Answers are grounded in this paper and cite their sources.
The aim of this study was to evaluate the effects of administering 325 mg of recombinant bovine somatotropin (rbST) at the initiation of the synchronization protocol (SYNCd) and/or on the day of embryo transfer (ETd) using a 2 × 2 experimental arrangement in Holstein heifer recipients. All heifers (n = 1,638; approximately 13 mo of age, first service only) were submitted to a fixed-time ET synchronization protocol consisting of CIDR insertion on D -8, CIDR removal and cloprostenol administration on D -3, and gonadorelin administration on D0. On D6, heifers were evaluated by ultrasonography for the presence of a corpus luteum (CL). On D7, grade 1 fresh in vitro-produced blastocysts were transferred. Administration of rbST at SYNCd did not affect estrus expression or the proportion of synchronized heifers that received an embryo. Pregnancy diagnosis was conducted on D29 in a randomly selected subset of heifers that received an embryo (n = 922) and subsequently on D36, D66, D85, and D120 by transrectal ultrasonography in all heifers submitted to ET. Our first hypothesis that rbST would increase pregnancy per ET (P/ET) and reduce pregnancy loss (PLOSS) was supported by rbST administration at SYNCd, but not by rbST at ETd or by rbST administration at both SYNCd and ETd. Administration of rbST at SYNCd resulted in an 18.2% relative increase in P/ET at D36 and a 30.1% relative decrease in PLOSS from D36 to D120. This corresponded to a 33.6% relative increase in P/ET at D120 in rbST-treated heifers at SYNCd. Subgroups of heifers were used to assess physiological parameters, including the diameter of the largest follicle at CIDR removal, CL volume and progesterone (P4) concentrations on D6, P4 and pregnancy-associated glycoprotein (PAG) concentrations on D29, and crown-rump length on D36. Our secondary hypothesis, that improvements in fertility would be associated with increased follicle, CL, and crown-rump size, as well as greater concentrations of P4 and PAG, was partially supported by rbST at SYNCd, but not by rbST at ETd or by rbST on both days. Larger crown-rump length, greater PAG, along with trends toward changes in P4, CL, and follicle size, may underlie the effects of rbST at SYNCd on fertility. Collectively, these results support the use of rbST at the initiation of synchronization to improve fertility and reduce pregnancy loss in ET programs, whereas administration on the day of ET did not offer any benefits. The observed physiological responses suggest potential mechanisms underlying these fertility effects, although the magnitude of some responses warrants further investigation.
No takes yet. Share an insight, caveat, or question.
Rebeis et al. (2026) studied this question.
Synapse has enriched 10 related papers. Consider them for comparative context: